Skip to main content
OpenTrials
Completed

NCT Number: NCT01131026

Efficacy and Safety Evaluation of Levofloxacin Triple Therapy for Helicobacter Pylori Eradication

Today, although the triple treatment with clarithromycin accepted as the primary treatment for Helicobacter pylori infection eradication is well tolerated, the eradication has been decreased to 65 %. However, the eradication resulting from TRIOL treatment with levofloxacin is expected to be 75 % or higher. If the target results can be reached, it will be concluded that TRIOL treatment with levofloxacin will be an alternative to the triple treatment with clarithromycin as the primary treatment.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Helicobacter Pylori Infection

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Erciyes University School of Medicine Hospital, Department of Internal Medicine and Gastroenterology

Kayseri, 38039, Turkey (Türkiye)

About this study

The primary end point in this study is appointed to be "Helicobacter pylori infection eradication with TRIOL treatment" and the secondary end point as "safety". The study involves the investigation of the efficacy and safety of the triple treatment consisting of 500 mg levofloxacin, 1000 mg amoxicillin and 30 mg lansoprazole on Helicobacter pylori eradication in 60 patients with Helicobacter pylori infection.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Consenting to an endoscopy
  • Signing the informed consent form
  • Not receiving Helicobacter pylori eradication treatment before
  • Showing Helicobacter pylori infection by rapid urease test and/or Giemsa staining
  • Being older than 18 years of age

Exclusion criteria

  • Being younger than 18 years of age
  • Receiving H. pylori eradication treatment previously
  • Having gastrectomy or vagotomy in medical history
  • Having gastric malignancy, including adenocarcinoma and lymphoma
  • Having other severe malignant disease
  • Previously having allergic reaction to antibiotics (amoxicillin, levofloxacin) and proton pump inhibitors (lansoprazole)
  • Using prompt pump inhibitors (lansoprazole) and antibiotics (amoxicillin, clarithromycin, levofloxacin) in the last 4 weeks
  • Having active upper GI bleeding in the last week
  • Being pregnant or lactating
  • Taking long term high dosages of aspirin, corticosteroid and other NSAIDs in the last 4 weeks
  • Taking any antibiotics or proton pump inhibitors other than the study medication during the study period
  • Taking antacids and/or H2-blockers during the study period
  • Taking bismuth compounds within four weeks prior to and during the study period
  • Having dysphasia or vomiting as major symptoms
  • Having psychiatric, neurological, or behavioral disorders that may interfere with the conduct or interpretation of the study
  • Having severe concomitant disease of the cardiovascular, pulmonic, hepatic, renal, hematological, lymphatic, metabolic, and endocrine system.
  • Having known uncontrolled hypertension
  • Being immunocompromised
  • Showing clinically significant abnormal vital signs
  • Having clinically significant abnormal ECG findings
  • Presenting clinically significant abnormal laboratory data at screening, or any abnormal laboratory value that could interfere with the assessment of safety
  • Being exposed to any investigational drug within 30 days prior to screening
  • Having known hypersensitivity to or contraindication against fluoroquinolones.
  • Having current diagnosis or known history of substance abuse.

Treatment and study plan

Levofloxacin

Drug

tablet, 500 mg, once a day for ten days

Other names: Floxilevo 500 mg Tablet

Amoxicillin

Drug

tablet, 1000 mg, once a day for ten days

Other names: Dentamax 1 gr Tablet

Lansoprazole

Drug

capsule, 30 mg, twice a day for ten days

Other names: Degastrol 30 mg Capsule

Primary outcomes

  1. Helicobacter pylori infection eradication

    Time frame: 6 weeks

    After 6 weeks from the end of the TRIOL treatment, demonstrating the ratio of patients who do not develop Helicobacter pylori infection by rapid urease test and Giemsa staining.

Secondary outcomes

  1. Safety

    Time frame: 6 weeks

    During the study all patients will be examined at the determined timepoints in the protocol in regard to any type of clinical adverse event. These examinations involve clinical and laboratory examinations of which the results will be recorded in the final study report and discussed with respect to the current literature.

Sponsors and collaborators

Lead sponsor

Deva Holding A.S.

Industry

Collaborators

  • TC Erciyes University
  • TNC Ilac Arastirma Gelistirme Danismanlik San. ve Tic. Ltd. Sti.

Registry information

Official study title

A Monocentric, Open-label, Efficacy and Safety Evaluation Study of the Triple Therapy of 500 mg Levofloxacin, 1000 mg Amoxicillin and 30 mg Lansoprazole on Helicobacter Pylori Eradication in 60 Patients Infected With H. Pylori

Important dates

Study start
2010
Primary completion
2011
Study completion
2011
First posted
May 26, 2010
Registry last updated
Aug 9, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.